Bayer : Q3 a beat on CropScience, guidance raised
>Q3 better than expected on sales, adjusted EBITDA and adjusted EPS - Bayer reported sales of € 9.78bn in sales, 5.5% better than our forecast (€ 9.272bn) and 7.3% better than the consensus (Vara; € 9.116bn). CropScience was the main driving factor with sales having been c. € 370m better than our forecast and c. € 540m better than the consensus. This also drove the adjusted EBITDA margin in CropScience, which came in at 12.2% vs 10.9% estimated (10.7% consensus). We a...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.